Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$11.64 USD
+0.10 (0.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $11.59 -0.05 (-0.43%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IOVA 11.64 +0.10(0.87%)
Will IOVA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IOVA
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates
Other News for IOVA
The Top 3 Biotech Stocks to Buy in April 2024
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts